Literature DB >> 11502797

Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension.

D J Torpy1, A W Bachmann, J E Grice, S P Fitzgerald, P J Phillips, J A Whitworth, R V Jackson.   

Abstract

Corticosteroid-binding globulin is a 383-amino acid glycoprotein that serves a hormone transport role and may have functions related to the stress response and inflammation. We describe a 39-member Italian-Australian family with a novel complete loss of function (null) mutation of the corticosteroid-binding globulin gene. A second, previously described, mutation (Lyon) segregated independently in the same kindred. The novel exon 2 mutation led to a premature termination codon corresponding to residue -12 of the procorticosteroid-binding globulin molecule (c.121G-->A). Among 32 family members there were 3 null homozygotes, 19 null heterozygotes, 2 compound heterozygotes, 3 Lyon heterozygotes, and 5 individuals without corticosteroid-binding globulin mutations. Plasma immunoreactive corticosteroid-binding globulin was undetectable in null homozygotes, and mean corticosteroid-binding globulin levels were reduced by approximately 50% at 18.7 +/- 1.3 microg/ml (reference range, 30-52 microg/ml) in null heterozygotes. Morning total plasma cortisol levels were less than 1.8 microg/dl in homozygotes and were positively correlated to the plasma corticosteroid-binding globulin level in heterozygotes. Homozygotes and heterozygote null mutation subjects had a high prevalence of hypotension and fatigue. Among 19 adults with the null mutation, the systolic blood pressure z-score was 12.1 +/- 3.5; 11 of 19 subjects (54%) had a systolic blood pressure below the third percentile. The mean diastolic blood pressure z-score was 18.1 +/- 3.4; 8 of 19 subjects (42%) had a diastolic blood pressure z-score below 10. Idiopathic chronic fatigue was present in 12 of 14 adult null heterozygote subjects (86%) and in 2 of 3 null homozygotes. Five cases met the Centers for Disease Control criteria for chronic fatigue syndrome. Fatigue questionnaires revealed scores of 25.1 +/- 2.5 in 18 adults with the mutation vs. 4.2 +/- 1.5 in 23 healthy controls (P < 0.0001). Compound heterozygosity for both mutations resulted in plasma cortisol levels comparable to those in null homozygotes. Abnormal corticosteroid-binding globulin concentrations or binding affinity may lead to the misdiagnosis of isolated ACTH deficiency. The mechanism of the association between fatigue and relative hypotension is not established by these studies. As idiopathic fatigue disorders are associated with relatively low plasma cortisol, abnormalities of corticosteroid-binding globulin may be pathogenic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502797     DOI: 10.1210/jcem.86.8.7724

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Cortisol binding globulin: more than just a carrier?

Authors:  Giovanni Cizza; Kristina I Rother
Journal:  J Clin Endocrinol Metab       Date:  2012-01       Impact factor: 5.958

Review 2.  Diagnosis and treatment of ACTH deficiency.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 3.  Chronic fatigue syndrome: the need for subtypes.

Authors:  Leonard A Jason; Karina Corradi; Susan Torres-Harding; Renee R Taylor; Caroline King
Journal:  Neuropsychol Rev       Date:  2005-03       Impact factor: 7.444

Review 4.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

Review 5.  Is chronic fatigue syndrome (CFS/ME) heritable in children, and if so, why does it matter?

Authors:  Esther Crawley; George Davey Smith
Journal:  Arch Dis Child       Date:  2007-09-05       Impact factor: 3.791

6.  Hyporesponsiveness to glucocorticoids in mice genetically deficient for the corticosteroid binding globulin.

Authors:  Helle Heibroch Petersen; Thomas K Andreassen; Tilman Breiderhoff; Jan Hinrich Bräsen; Herbert Schulz; Volkmar Gross; Hermann-Josef Gröne; Anders Nykjaer; Thomas E Willnow
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

Review 7.  Regulation of cortisol bioavailability--effects on hormone measurement and action.

Authors:  Ilias Perogamvros; David W Ray; Peter J Trainer
Journal:  Nat Rev Endocrinol       Date:  2012-08-14       Impact factor: 43.330

8.  Clinical manifestations of highly prevalent corticosteroid-binding globulin mutations in a village in southern Italy.

Authors:  Giovanni Cizza; Livia Bernardi; Nicoletta Smirne; Raffaele Maletta; Carmine Tomaino; Angela Costanzo; Maura Gallo; John G Lewis; Silvana Geracitano; Maria Beatrice Grasso; Giuseppe Potenza; Cosimo Monteleone; Giacomino Brancati; Jui T Ho; David J Torpy; Amalia C Bruni
Journal:  J Clin Endocrinol Metab       Date:  2011-07-27       Impact factor: 5.958

9.  Functional implication of an Arg307Gly substitution in corticosteroid-binding globulin, a candidate gene for a quantitative trait locus associated with cortisol variability and obesity in pig.

Authors:  Véronique Guyonnet-Dupérat; Nicoline Geverink; Graham S Plastow; Gary Evans; Olga Ousova; Christian Croisetière; Aline Foury; Elodie Richard; Pierre Mormède; Marie-Pierre Moisan
Journal:  Genetics       Date:  2006-05-15       Impact factor: 4.562

10.  Vitamin D-binding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo.

Authors:  Lee A Zella; Nirupama K Shevde; Bruce W Hollis; Nancy E Cooke; J Wesley Pike
Journal:  Endocrinology       Date:  2008-03-27       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.